Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Ruilope

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Journal of Hypertension|November 6, 2019
Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trialsMaria-Eleni Alexandrou, Aikaterini Papagianni, Apostolos Tsapas, et al.
Blood Pressure|July 7, 2007
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of HypertensionLuis Ruilope, Sverre E Kjeldsen, Alejandro de la Sierra, et al.
Journal of Hypertension|December 2, 2016
Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension: results from the Global SYMPLICITY RegistryDominik Linz, Giuseppe Mancia, Felix Mahfoud, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 6, 2020
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenoneRajiv Agarwal, Stefan D Anker, George Bakris, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 5, 2013
Updated ESH position paper on interventional therapy of resistant hypertensionRoland E Schmieder, Josep Redon, Guido Grassi, et al.
Journal of Hypertension|April 4, 2012
ESH position paper: renal denervation - an interventional therapy of resistant hypertensionRoland E Schmieder, Josep Redon, Guido Grassi, et al.
American Heart Journal|June 22, 2015
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetesErland Erdmann, Robert Califf, Hertzel C Gerstein, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|November 20, 2025
Sex stratified analysis of patients with resistant hypertension from the Global SYMPLICITY Registry of renal denervationAnastasia S Mihailidou, Felix Mahfoud, Markus Schlaich, et al.
Journal of the American College of Cardiology|June 13, 2020
Renal Denervation in High-Risk Patients With HypertensionFelix Mahfoud, Giuseppe Mancia, Roland Schmieder, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 9, 2024
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysisBertram Pitt, Rajiv Agarwal, Stefan D Anker, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Journal of Hypertension|November 6, 2019
Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trialsMaria-Eleni Alexandrou, Aikaterini Papagianni, Apostolos Tsapas, et al.
Blood Pressure|July 7, 2007
The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of HypertensionLuis Ruilope, Sverre E Kjeldsen, Alejandro de la Sierra, et al.
Journal of Hypertension|December 2, 2016
Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension: results from the Global SYMPLICITY RegistryDominik Linz, Giuseppe Mancia, Felix Mahfoud, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 6, 2020
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenoneRajiv Agarwal, Stefan D Anker, George Bakris, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|June 5, 2013
Updated ESH position paper on interventional therapy of resistant hypertensionRoland E Schmieder, Josep Redon, Guido Grassi, et al.
Journal of Hypertension|April 4, 2012
ESH position paper: renal denervation - an interventional therapy of resistant hypertensionRoland E Schmieder, Josep Redon, Guido Grassi, et al.
American Heart Journal|June 22, 2015
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetesErland Erdmann, Robert Califf, Hertzel C Gerstein, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|November 20, 2025
Sex stratified analysis of patients with resistant hypertension from the Global SYMPLICITY Registry of renal denervationAnastasia S Mihailidou, Felix Mahfoud, Markus Schlaich, et al.
Journal of the American College of Cardiology|June 13, 2020
Renal Denervation in High-Risk Patients With HypertensionFelix Mahfoud, Giuseppe Mancia, Roland Schmieder, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|October 9, 2024
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysisBertram Pitt, Rajiv Agarwal, Stefan D Anker, et al.
Pageof 7